Download Latest CIC Questions

The correct answer is C, "Rate of multi-drug resistant organisms acquisition," as it represents an example of an outcome measure. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, outcome measures are indicators that reflect the impact or result of infection prevention and control interventions on patient health outcomes or the incidence of healthcare-associated infections (HAIs). The rate of multi-drug resistant organisms (MDRO) acquisition directly measures the incidence of new infections caused by resistant pathogens, which is a key outcome affected by the effectiveness of infection control practices (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.4 - Evaluate the effectiveness of infection prevention and control interventions).

Option A (hand hygiene compliance rate) is an example of a process measure, which tracks adherence to specific protocols or practices intended to prevent infections, rather than the resulting health outcome. Option B (adherence to environmental cleaning) is also a process measure, focusing on the implementation of cleaning protocols rather than the end result, such as reduced infection rates. Option D (timing of preoperative antibiotic administration) is another process measure, assessing the timeliness of an intervention to prevent surgical site infections, but it does not directly indicate the outcome (e.g., infection rate) of that intervention.

Outcome measures, such as the rate of MDRO acquisition, are critical for evaluating the success of infection prevention programs and are often used to guide quality improvement initiatives. This aligns with CBIC’s emphasis on using surveillance data to assess the effectiveness of interventions and inform decision-making (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 - Use data to guide infection prevention and control strategies). The focus on MDRO acquisition specifically highlights a significant healthcare challenge, making it a prioritized outcome measure in infection control.

The Certification Study Guide (6th edition) classifies endovaginal ultrasound probes as semi-critical devices because they come into contact with mucous membranes. As such, they require high-level disinfection (HLD) between patients, not sterilization, unless the manufacturer specifically requires it. This immediately eliminates option A, which incorrectly states sterilization is required.

Option B is incorrect because probe covers or sheaths do not eliminate the risk of contamination. Numerous studies referenced in infection prevention literature and reflected in the study guide demonstrate that probe covers can fail, tear, or leak, allowing microorganisms—including viruses—to contaminate the probe surface. Therefore, HLD is required regardless of sheath use.

Option C is incorrect because critical items, by definition, enter sterile tissue or the vascular system. Endovaginal probes contact mucous membranes only and are therefore not critical items under the Spaulding Classification System.

Option D is correct because endovaginal probes may be contaminated with human papillomavirus (HPV) prior to examination, even when probe covers are used. HPV is particularly concerning due to its resistance to some low-level disinfectants and its ability to persist on surfaces. The study guide highlights HPV as a key organism driving strict reprocessing requirements for these probes.

This question reflects a high-yield CIC exam concept: probe covers do not replace high-level disinfection, and viral contamination—including HPV—remains a significant risk.

Before initiating airborne precautions, the infection preventionist must first confirm the clinical suspicion of active TB.

Step-by-Step Justification:

Confirming Active TB:

A positive tuberculin skin test (TST) alone does not indicate active disease​.

A review of chest X-ray, symptoms, and risk factors is needed.

Medical Record Review:

Past TB history, imaging, and sputum testing are key to diagnosis​.

Not all TST-positive patients require isolation.

Why Other Options Are Incorrect:

A. Contact the roommate's physician to initiate TST: Premature, as no confirmation of active TB exists yet.

C. Report findings to Employee Health for staff follow-up: Should occur only after TB confirmation.

D. Transfer to airborne isolation immediately: Airborne isolation is necessary only if active TB is suspected based on clinical findings​.

CBIC Infection Control References:

The Certification Study Guide (6th edition) emphasizes that when a specific product lot is suspected or confirmed to be contaminated, the first priority is containment and traceability. The infection preventionist must promptly identify where the implicated lot is located within the facility so it can be removed from use, quarantined, and managed according to recall or manufacturer instructions. This step prevents further patient exposure and preserves the ability to conduct an accurate risk assessment.

Locating the affected dressings allows the facility to determine how widely the product has been distributed, whether it is still in use, and which clinical areas may be affected. This information is essential before taking additional actions such as patient notification or broad product removal. The study guide stresses that responses must be proportionate and evidence-based, avoiding unnecessary disruption or alarm.

The other options represent actions that may be considered later, depending on findings. Removing all dressings from the same manufacturer is overly broad when only one lot is implicated. Notifying discharged patients is premature unless patient exposure and risk have been confirmed. Purchasing from a different manufacturer does not address the immediate need to control and investigate the current issue.

CIC exam questions often focus on sequencing of actions during product contamination events. Correctly identifying and isolating the affected product lot is the foundational step that enables safe, effective follow-up and regulatory compliance.